Long-term efficacy and safety of Limaprost for the treatment of Lumbar Spinal Stenosis

Long-term efficacy and safety of Limaprost for the treatment of Lumbar Spinal Stenosis - Long-term efficacy of Limaprost for LSS

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012918

Enrollment

300

Registered

2014-03-01

Start date

2014-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lumbar Spinal Stenosis

Interventions

Limaprost alfadex(15 micro g/day), 1yrs.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Lumbar spinal stenosis identified by Diagnostic tool and MRI

Exclusion criteria

Exclusion criteria: 1) SLR positive 2) Current or history of critical limb ischemia 3) Uncontrolled DM 4) Diagnosis of RA 5) Clinically significant neurological or skeletal dysfunction 6)Unlikely to be compliant with protocol

Design outcomes

Primary

Measure	Time frame
Zurich claudication questionnaire	—

Secondary

Measure	Time frame
Intermittent claudication MOS-Short Form 12 Numeric Rating Scale(NRS) for pain and numbness intensity Measurement of treatment satisfaction Combined medicine and treatment Surgery rate EQ-5D	—

Countries

Japan

Contacts

Public ContactHiroshi Hashizume

Wakayama Medical University Orthopaedic Surgery

hashizum@wakayama-med.ac.jp073-441-0645

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026